Tej P. Singh: Difference between revisions
Afrankwiki (talk | contribs) No edit summary |
Afrankwiki (talk | contribs) |
||
| Line 51: | Line 51: | ||
|- |
|- |
||
|- style="background: black; color: white" |
|- style="background: black; color: white" |
||
|<!--column1-->Structure of |
|<!--column1-->Structure of PGRP |
||
|<!--column2-->Structure of Lactoperoxidase |
|<!--column2-->Structure of Lactoperoxidase |
||
|<!--column3-->Structure of Lactoferrin |
|<!--column3-->Structure of Lactoferrin |
||
Revision as of 11:47, 18 March 2013
Tej P. Singh | |
|---|---|
 | |
| Nationality | Indian |
| Citizenship | India |
| Alma mater | Indian Institute of Science, Bangalore |
| Known for | Protein Structure Determination, Peptide Design, Drug Design |
| Awards | Goyal Prize 2010 for Life Sciences Distinguished Biotechnology Research Professor (DBT) (2009) Distinguished Biotechnologist (DBT) (2006) GN Ramachandran Gold Medal CSIR) |
| Scientific career | |
| Fields | Rational structure based Drug Design |
| Institutions | All India Institute of Medical Sciences |
Tej P. Singh (तेज प सिंह) is an eminent Indian biophysicist and a scientific leader who has made original and novel contributions in the fields of Rational Structure based drug design, Protein Structure biology and X-ray crystallography. He has played an active role in the development of research programmes on drug design in the fields of Tuberculosis, Inflammation, Cancer, Epilepsy, Gastropathy and Arthritis in India. He has published more than 350 research papers in leading international journals and has submitted the highest number of protein structures in India in the Protein Data Bank (PDB).
He has mentored more than 70 MSc, PhD, MD and Post-Doc students who are currently independent group leaders in leading scientific institutions in various parts of the country. He has made significant collaborations with other academic institutions as well as industry partners all over the country. He has been nominated as a fellow of six national and international academies, namely, the Third World Academy of Sciences, Indian National Science Academy, National Academy of Sciences, Indian Academy of Sciences, Alexander von Humboldt Foundation and Biotech Research Society of India.
He has been awarded various national and international awards over the years, for instance, the Jawaharlal Nehru Birth Centenary Lecture Award of INSA (2011), Annual Award of the Instrumentation Society of India (2011), CSIR Foundation Day Lecture award (2010), Goyal Prize in Life Sciences (2007), Professor G.N. Ramachandran CSIR Gold Medal for the Excellence in Biological Sciences and Technology (2006) and, Professor G.N. Ramachandran 60th Birthday Commemoration INSA Medal (2006).
Education
Professor Tej Singh obtained his Masters in Science in first rank from the University of Allahabad. He started his research career in 1971 as a graduate student at the Indian Institute of Science, Bangalore. He obtained his Ph. D degree in the mid 70's working on the crystal structure determinations and design of anti-inflammatory analgesics for new drug discovery.
Professional career
Soon after obtaining his Ph. D degree, he worked about a year (1977) as a lecturer at the University of Indore. He then spent more than two years (1978–1980) as an Alexander von Humboldt / Max-Planck, post doctoral fellow in the German laboratory of Professor Robert Huber, who later received the Nobel Prize. After his return to India he worked as a reader at Sardar Patel University (1980–83) and an Additional Professor (1984–85) in the Department of Biophysics at the All India Institute of Medical Sciences, New Delhi. He was appointed Professor and Head of the Department in 1986, where he established a flourishing school of structural biology and new drug discovery.
Work
The three-dimensional structures of various proteins including lactoperoxidase [1], Peptidoglycan recognition Protein[2][3][4][5][6] and lactoferrin [7][8][9]from several species, ribosome inactivating proteins[10], bifunctional inhibitor proteins from plant seeds and various serine proteases and their inhibitors have been determined by his group. The elaborate structural studies of proteins from several important systems as potential drug targets such as phospholipase A2, cyclooxygenase, lipoxygenase, endothelin receptor, endothelin converting enzyme, breast cancer regression proteins and matrix metanosomal proteins as well as their complexes with natural and designed synthetic ligands have been carried out. His laboratory has submitted more than 301 sets of proteins structure coordinates in the protein data bank (PDB) which makes it the highest number in India. Initially, he had contributed significantly on the structure - function studies of a number of antipyretic, analgesic and anti-inflammatory agents and then on antibacterial sufonamides and their derivatives. He had developed the rules of peptide design with alpha, beta – dehydro - amino acids through extensive studies using syntheses, and X-ray and NMR structure determinations. These design rules are being exploited for making specific peptides to act as tight inhibitors of target enzymes and potent antagonists of target receptors for eventually leading to useful therapeutic agents.
As part of his protein structural studies, a large number of structures of lactoferrin proteins from various species in iron-saturated and apo-forms as well as those of its proteolytically generated monoferric functional N- and C-lobes have been determined in his laboratory through which it was demonstrated that large-scale conformational changes occur in the structures of lactoferrins upon iron-binding and iron-release, cations other than ferric ion also bind to the iron-binding cleft but with lower affinity, similarly anions other than carbonate/bicarbonate can also bind with reduced potency, and bilobal lactoferrin can be converted into two functional N-terminal and C-terminal lobes with proteinase K. These studies have provided valuable insights into the structural basis of iron-binding and iron-release in lactoferrins and their roles as antibacterial agents and in other therapeutic applications. While carrying out enzymatic cleavage of lactoferrin proteins, a novel antifungal decapeptide was discovered whose excellent potency against bacterial infections has been established.
His group has carried out extensive structural studies of phospholipase A2 enzymes and their complexes with various natural compounds, substrate analogues, non-steroidal anti-inflammatory agents and designed peptides. The new molecules have also been designed against cyclooxygenase and lypoxygenase. The enzymes phospholipase A2, cyclooxygenase and lypoxygenase are involved in the production of pro-inflammatory compounds collectively called as eicosanoids. He has already developed several highly potent inhibitors that are under consideration for further evaluation as anti-inflammatory agents. His group has been practicing the rational approach of structure-based drug design for developing therapeutic agents against various inflammatory disorders such as rheumatism and arthritis using PLA2, COX-2 and LOX enzymes as macromolecular targets.
His group has determined the crystal structures of several secretory glycoproteins isolated from dry secretions of various mammalian species including humans. This is a new class of proteins, first time detected whose functions and structures were unknown. These proteins are implicated as protective signaling factors in the large-scale tissue remodeling processes. Their role in the breast cancers as protective factors for the breast cancer cells makes them important targets for structure - based drug design and offers opportunities for developing new therapeutic agents against breast cancer. He has been able to design several peptides that bind to these proteins with potencies ranging up to 10-7 M.
The crystal structures of the complexes of these proteins with designed peptides have helped in identifying the site of binding in this protein. The structures of the complexes with various oligosachharides have provided information about the potencies of sugar binding. It also indicated the type and nature of sugars that will bind to this class of proteins specifically. Furthermore, several crystal structures of the ternary complexes of these proteins with peptides and sugars have helped in understanding the mode of binding of these proteins to cell surface receptors. He initiated a new programme on Clinical Proteomics in which it is intended to characterize all the proteins that are expressed during various patho/physiological conditions. The newly identified proteins will either be useful as biomarkers or they may be associated with the progression of diseases making them important targets for drug design. He has published more than 350 research papers in the leading journals.
|
|
|
|
| Structure of PGRP | Structure of Lactoperoxidase | Structure of Lactoferrin | Structure of SPX-40 |
|
|
|
|
| Structure of Phycoerythrin | Structure of Neurotoxin | Structure of Viscumin | Structure of Complex of ZAG and PIP |
Awards and honors
Goyal Prize for Life Sciences, 2010
Distinguished Biotechnology Research Professor (DBT), 2009
GN Ramachandran Gold Medal for excellence in Science and Technology (CSIR), 2006
Distinguished Biotechnologist (DBT), 2006
Vice President, Indian National Science Academy, 2007–2009
JC Bose Memorial Award, 2005
Alexander von Humboldt Fellow, 1977
Canadian Development Agency Award, 1999
Fellow of the Indian Academy of Sciences, 1994
Fellow of the National Academy of Sciences, 1998
Fellow of the Indian National Science Academy, 2000 -
Fellow of the Third World Academy of Sciences : F.T.W.A.S. 2003 -
Member of the Commission on Biological Macromolecules of the International Union of Crystallography (IUCr) (2005–2008)
Executive member of the International Union of Pure and Applied Biophysics (IUPAB) (2002–2005)
Member Secretary of the INSA National Committee for IUPAB (1988–91)
Member of the INSA National Committee for International Union of Pure and Applied Biophysics (IUPAB) (1985–88)
Member of the INSA National Committee for International Union of Crystallography (IUCr) (2000–2003)
Ex-officio member of the Joint National Committee of INSA for IUPAB and IUCr (2002–2005), (2005–2008)
Member of a committee to select fellows for Indian National Science Academy (2001–2003)
Member of the Committee to select fellows for the Indian Academy of Sciences, 2005
Member of the Indian Biophysical Society since 1977
Member of the Society of Biological Chemists of India, 1982
Vice President of the Indian Biophysical society (1994–1996)
Member of the American Society for Biochemistry and Molecular Biology (ASBMB), since 2000
Member Technology Development Board on Pharmaceutical Industry (2002)
Member of the Senate of Indian Institute of Technology Delhi, (2001–2002)
Chairman of the DST Committee for the Fast Track Programme in life Sciences (2002–2004), (2005–2007)
Member of the Apex Committee of the DBT for the programme support at I.I.Sc. Bangalore (1998–2001), (2002–2004), (2005–2008)
Member of the Programme Advisory Committee of DST on Biochemistry, Biophysics, Molecular Biology including Microbiology (1996–1998), (1999–2001)
Member of the DBT task force on Basic Biology / Modern Biology (1996–1998), (1999–2001)
Member of the DBT task force on Infrastructure (2001–2003), (2004–2006), (2006–2008)
Member of the DBT task force on Bioinformatics (1994–1996)
Member of the Advisory Committee of Biotechnology Teaching Programme of the Biotechnology Centre, JNU (2002)
Member of the Executive Committee of the Bioinformatics Centre at Madurai Kamraj University (2002–2003)
Member of the Academic Committee of the Biotechnology Unit of AMU, Aligarh (2004–2006)
Member of the Research Area Panel of the National Institute of Immunology (1994–1996)
Member of the Special Committee of the School of Life Sciences, JNU (1988–1990), (1991–1993)
Member of the Special Committee of the Centre for Biotechnology, JNU (1991–1993), (1994–1996), (1997–1999), (2000–2002), (2003–2005)
Member of the Special Committee of the Special Centre of Molecular Medicine, JNU (2001–2003), (2004–2006)
Member of the Special Committee of the School of Environmental Sciences, JNU (2001–2003), (2004–2006)
Member of the Academic Committee of the Nuclear Science Centre, New Delhi, (2002–2004), (2004–2006)
Member of the Academic Committee of Central Drug Research Institute, Lucknow, (2005–2006)
Member of the Academic Committee of the Institute of Microbial Technology, Chandigarh, (2005–2006)
Member of the Executive Council of the Centre of Bioinformatics, Institute of Microbial Technology, Chandigarh, 2005
Member of the Academic Council of the Central University of Hyderabad, 2006–2007
Executive member of the Council of the International Union of Pure and Applied Biophysics (IUPAB) (2005–2008)
K.K.Foundation National Award for Science and Technology, 2001
Chairman of the Fast-Track Programme of DST in Life Sciences, 2001–2003
Member of the Technology Development Board on Pharmaceutical Industry, 2002–2003
Executive member of the Council of International Union of Pure and Applied Biophysics, 2002–2005
Max-Planck - Humbodt Award - 1999
Canadian Development Agency Award - 1991
Danish International Development Agency Award - 1978
First Rank in M.Sc. in the University of Allahabad - 1971
External links
- http://dst.gov.in/whats_new/press-release07/biotech-award.htm
- http://www.jbc.org/cgi/reprint/M208967200v1.pdf
- http://timesofindia.indiatimes.com/articleshow/753224.cms
- http://www.bio-medicine.org/medicine-news/Five-New-Anti-Inflammatory-Compounds-Produced-By-Indian-Scientists-6838-1/
- http://pib.nic.in/release/release.asp?relid=25773
References
- ^ Singh, A..; Singh, N.; Sharma, S.; Singh, S.B.; Kaur, P.; Bhushan, A.; Srinivasan, A.; Singh, T.P. (14 December 2007). "Crystal structures of lactoperoxidase at 2.4 A resolution". Journal of Molecular Biology. 376 (4): 1060–1075. PMID 18191143.
- ^ Sharma, P.; Dube, D.; Sinha, M.; Mishra, B.; Dey, S; Mal, G.; Pathak, K.M.; Kaur, P.; Sharma, S.; Singh, T.P. (22 July 2011). "Multiligand specificity of pathogen-associated molecular pattern-binding site in peptidoglycan recognition protein". Journal of Biological Chemistry. 286 (36): 31723–30. PMID 21784863.
{{cite journal}}: Cite has empty unknown parameters:|1=and|2=(help) - ^ Sharma, P.; Yamini, S.; Dube, D.; Singh, A.; Sinha, M.; Dey, S.; Mitra, D.K.; Kaur, P.; Sharma, S.; Singh, T.P. (09 May 2012). "Structural studies on molecular interactions between camel peptidoglycan recognition protein, CPGRP-S, and peptidoglycan moieties N-acetylglucosamine and N-acetylmuramic acid". Journal of Biological Chemistry. 287 (26): 22153–22164. PMID 22573327.
{{cite journal}}: Check date values in:|date=(help); Cite has empty unknown parameters:|1=,|2=, and|3=(help) - ^ Sharma, P.; Yamini, S.; Dube, D.; Singh, A.; Mal, G.; Pandey, N.; Sinha, M.; Singh, A.K.; Dey, S.; Kaur, P.; Mitra, D.K.; Sharma, S.; Singh, T.P. (10 November 2012). "Structural basis of the binding of fatty acids to peptidoglycan recognition protein, PGRP-S through second binding site". Archives of Biochemistry and Biophysics. 529 (1): 1–10. PMID 23149273.
{{cite journal}}: Cite has empty unknown parameters:|1=and|2=(help) - ^ Sharma, P.; Singh, N.; Sinha, M.; Sharma, S.; Perbandt, M.; Betzel, C.; Kaur, P.; Srinivasan, T.P.; Singh (19 March 2008). "Crystal structure of the peptidoglycan recognition protein at 1.8 A resolution reveals dual strategy to combat infection through two independent functional homodimers". Journal of Molecular Biology. 378 (4): 923–932. PMID 18395744.
{{cite journal}}: Cite has empty unknown parameters:|1=and|2=(help) - ^ Sharma, P.; Dube, D.; Sinha, M.; Yadav, S.; Kaur, P.; Sharma, S.; Singh, T.P. (9 January 2013). "Structural insights into the dual strategy of recognition by peptidoglycan recognition protein, PGRP-S: structure of the ternary complex of PGRP-S with lipopolysaccharide and stearic acid". Plos One. 8 (1): e53756. PMID 23326499.
{{cite journal}}: Cite has empty unknown parameter:|1=(help) - ^ Sharma, S.; Jasti, J.; Kumar, J.; Mohanty, A.K.; Singh, T.P. (08 August 2003). "Crystal structure of a proteolytically generated functional monoferric C-lobe of bovine lactoferrin at 1.9A resolution". Journal of Molecular Biology. 331 (2): 485–96. PMID 12888354.
{{cite journal}}: Check date values in:|date=(help); Cite has empty unknown parameter:|1=(help) - ^ Khan, J.A.; Kumar, P.; Paramasivam, M.; Yadav, R.S.; Sahani, M.S.; Sharma, S.; Srinivasan, A.; Singh, T.P. (08 June 2001). "Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 A resolution and structural basis of its dual role". Journal of Molecular Biology. 309 (3): 751–761. PMID 11397094.
{{cite journal}}: Check date values in:|date=(help); Cite has empty unknown parameter:|1=(help) - ^ Mir, R.; Singh, N.; Vikram, G.; Kumar, R.P.; Sinha, M.; Bhushan, A.; Kaur, P.; Srinivasan, A.; Sharma, S.; Singh, T.P. (16 December 2009). "The structural basis for the prevention of nonsteroidal antiinflammatory drug-induced gastrointestinal tract damage by the C-lobe of bovine colostrum lactoferrin". Biophysical Journal. 97 (12): 3178–3186. PMID 20006955.
{{cite journal}}: Cite has empty unknown parameters:|1=,|2=, and|3=(help) - ^ Kushwaha, G.S.; Pandey, N.; Sinha, M.; Singh, S.B.; Kaur, P.; Sharma, S.; Singh, T.P. (April 2012). "Crystal structures of a type-1 ribosome inactivating protein from Momordica balsamina in the bound and unbound states". Biochemica Biophysica Acta. 1824 (4): 679–91. PMID 22361570.
{{cite journal}}: Cite has empty unknown parameters:|1=and|2=(help)